Core Viewpoint - The Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that the defendants made false and misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, which led to investor damages when the truth was revealed [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in recent years [5].

Core Insights - Kura Oncology hosted an ASH 2025 analyst and investor event, highlighting significant advancements in menin inhibitors for acute leukemia [1][2] Company Overview - The presentation was led by Troy Wilson, the President and CEO of Kura Oncology, indicating a focus on recent developments and data presented at the conference [1] - The agenda included a review of data presented in an oral session at ASH, emphasizing the importance of the findings for the company and the industry [2]

The company appears to be on track to develop a commercialized product through its drug discovery system.Recursion Pharmaceuticals (RXRX +2.33%) was in the headlines on Monday, and for the right reason. One of the biotech company's investigational drugs did well in a clinical trial, and investors rewarded the company by trading its stock more than 2% higher on the news. A very encouraging trialBefore market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The d ...

Core Insights - Genentech announced new data on Lunsumio (mosunetuzumab-axgb) showcasing its potential in earlier treatment lines for lymphoma, presented at the 67th American Society of Hematology Annual Meeting [1] Group 1: Efficacy and Clinical Data - Lunsumio shows promise in combination with lenalidomide for relapsed or refractory follicular lymphoma, with a complete response rate of 87.0% in a Phase III study [2] - Long-term follow-up data from the Phase Ib/II GO40516 study indicated an overall response rate of 77.5% for Lunsumio plus Polivy in relapsed or refractory large B-cell lymphoma, compared to 50.0% for Rituxan plus Polivy [3] - Five-year follow-up data from the Phase II GO29781 study reported a 78.5% overall survival rate for intravenous Lunsumio in third-line or later follicular lymphoma [5] Group 2: Regulatory Status and Approvals - Lunsumio is approved in over 60 countries for patients with follicular lymphoma who have received at least two prior systemic therapies, with recent approval from the European Commission [6] - A decision from the US Food and Drug Administration regarding Lunsumio is expected soon [6] Group 3: Company Strategy and Commitment - Genentech is committed to exploring new formulations and combinations of Lunsumio and other bispecific antibodies to enhance patient experience and treatment options [7] - The company has been developing innovative treatments in hematology for over 20 years, focusing on improving outcomes for patients with blood diseases [49]

Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option for those unsuitable for chemotherapy Additional early data show promising efficacy of epcoritamab combination regimens in patients with RT Results underscore the potential of epcoritamab as a versatile therapy for a broad range of B-cell malignancies Genmab A/S ...

PresentationGood morning, and welcome to the Cogent Biosciences webcast. I will now turn the call over to Christi Waarich, Senior Director of Investor Relations.Christi WaarichSenior Director of Investor Relations Thank you, operator. Today's call will cover our SM updates announced over the weekend and this morning. You can find the press releases in the Investors and Media section of our website at cogentbio.com. Before we get started, please be reminded that remarks made during this webcast may be forwa ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing therapies leveraging PLK1 inhibition for various cancers [4] - Clinical data from a Phase 1 trial of onvansertib in chronic myelomonocytic leukemia (CMML) will be presented at the 67th American Society of Hematology Annual Meeting [1][3] Clinical Trial Results - In a Phase 1 dose escalation trial involving 9 patients, onvansertib as a monotherapy was well-tolerated and showed preliminary efficacy in approximately 40% of patients, with one patient achieving an optimal marrow response at the 9 mg/m dose [2] - The results support onvansertib's activity as a single agent in both hematologic and solid tumors, although the company does not plan to develop onvansertib specifically for CMML [2] Presentation Details - The poster presentation titled "Phase 1 clinical trial assessing the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in Relapsed/Refractory myeloproliferative chronic myelomonocytic leukemia (CMML)" will be delivered by Mrinal Patnaik, MD, MBBS, from Mayo Clinic [3] - The presentation is scheduled for December 8, 2025, from 6:00-8:00 PM EST as part of the Myelodysplastic Syndromes session [3] Company Overview - Cardiff Oncology's lead asset, onvansertib, is being evaluated in combination with standard of care therapies for indications such as RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer [4] - The company's development strategy aims to target tumor vulnerabilities to overcome treatment resistance and provide superior clinical benefits compared to standard therapies [4]

Group 1 - Protara Therapeutics, Inc. has closed its underwritten public offering of 13,043,479 shares at a price of $5.75 per share, generating approximately $75 million in gross proceeds before deductions [1] - The company has granted underwriters a 30-day option to purchase an additional 1,956,521 shares at the public offering price [1] - Protara plans to use the net proceeds from the offering to fund the clinical development of TARA-002 and other clinical programs, as well as for working capital and general corporate purposes [1] Group 2 - J.P. Morgan, TD Cowen, and Piper Sandler served as joint book-running managers for the offering, with LifeSci Capital as the lead manager and H.C. Wainwright & Co. as a manager [2] - The shares were issued under an effective shelf registration statement on Form S-3, declared effective by the SEC on November 14, 2023 [3]

Core Insights - AbCellera will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [1] - A live audio webcast of the presentation will be available on AbCellera's Investor Relations website, with a replay accessible afterward [1] Company Overview - AbCellera is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines [2] - The company's areas of focus include endocrinology, women's health, immunology, and oncology [2] - More information about the company can be found on their website [2]